Cargando…
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
INTRODUCTION: BNT162b1 is a lipid nanoparticle-formulated, nucleoside-modified mRNA SARS-CoV-2 vaccine. Here, we report safety and immune persistence data following a primary two-dose vaccination schedule administered 21 days apart. METHODS: Immune persistence was determined at month 3 in 72 younger...
Autores principales: | Li, Jingxin, Hui, Ai-Min, Zhang, Xiang, Ge, Lei, Qiu, Yuanzheng, Tang, Rong, Ye, Huayue, Wang, Xiyuan, Lin, Mei, Zhu, Zhongkui, Zheng, Jianfei, Qiu, Jingjun, Lagkadinou, Eleni, Shpyro, Svetlana, Ozhelvaci, Orkun, Türeci, Özlem, Khondker, Zakaria, Yin, Wanrong, Shishkova, Yoana, Jia, Siyue, Pan, Hongxing, Peng, Fuzhong, Ma, Zhilong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Muik, Alexander, Şahin, Uğur, Zhu, Li, Zhu, Fengcai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245386/ https://www.ncbi.nlm.nih.gov/pubmed/35771353 http://dx.doi.org/10.1007/s12325-022-02206-1 |
Ejemplares similares
-
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
por: Hui, Ai-Min, et al.
Publicado: (2022) -
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022) -
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022) -
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
por: Jin, Pengfei, et al.
Publicado: (2021) -
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
por: Quandt, Jasmin, et al.
Publicado: (2022)